Puli pharmaceutical: etibatide injection approved by MHRA in the UK

Puli pharmaceutical announced in the evening of August 6 that the company had recently received the approval notice for the listing application of etibatide injection issued by the UK drug and Health Products Administration (MHRA), which indicated that etibatide injection had the marketing qualification in the UK market Etibatide is a receptor antagonist of platelet glycoprotein Ⅱ B / Ⅲ a The ischemic state caused by thrombosis can be reversed by selective and reversible inhibition of the final common pathway of platelet aggregation It is suitable for the treatment of patients with acute coronary syndrome Etibatide injection was initially developed by cor therapeutics, Inc and was approved to be listed in the United States in May 1998 Now Merck is responsible for the sales It was approved to be listed in Europe in July 1999 and now GlaxoSmithKline is responsible for the sales The trade names of etibatide injection are Integrilin, which has been widely sold in the world After the successful research and development of etibatide injection of Puli pharmaceutical, it has been applied for registration in many countries It has obtained the Dutch listing license in February 2018, the German listing license in July 2018, and the U.S listing license in January 2019 Recently, it has received the approval notice from MHRA in the UK, which indicates that etibatide injection produced by Puli pharmaceutical has the marketing qualification in the UK market It will have a positive impact on the company's expansion of the UK market.